Education
About Us
Working with TipRanks
Follow Us
Metsera, Inc. (MTSR)
NASDAQ:MTSR
MTSR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.30 - $37.99
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.02M
Market Cap
$3.00B
Enterprise Value$1.25B
Total Cash (Recent Filing)$588.34M
Total Debt (Recent Filing)$9.73M
Price to Earnings (P/E)―
Beta1.98
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding105,055,534
10 Day Avg. Volume1,030,676
30 Day Avg. Volume1,018,545
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.98
Forecast
1Y Price Target
$47.00Price Target Upside96.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Metsera, Inc. News
PremiumCompany Announcements
Metsera, Inc. Reports Positive Phase 1 Trial ResultsBulls Say, Bears Say
Bulls Say
Clinical DevelopmentsMetsera announced positive results for its ultra long-acting injectable amylin MET-233i.
Leadership And StrategyMTSR's leadership has a strong execution track record in cardiometabolic drug development, which adds confidence in their strategy.
Market PotentialMetsera is breaking into the obesity market, which is expected to reach $170 billion by 2030, offering significant growth potential.
Bears Say
Competition And Market ChallengesThe highly competitive landscape in the obesity market could pose challenges, despite the promising outlook for MTSR's lead assets.
Ownership Overview
30.74% Insiders
7.43% Mutual Funds
24.41% Other Institutional Investors
35.30% Public Companies and Individual Investors
MTSR FAQ
What was Metsera, Inc.’s price range in the past 12 months?
Metsera, Inc. lowest stock price was $12.30 and its highest was $37.99 in the past 12 months.
What is Metsera, Inc.’s market cap?
Metsera, Inc.’s market cap is $3.00B.
When is Metsera, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Metsera, Inc.’s earnings last quarter?
Metsera, Inc. released its earnings results on Mar 26, 2025. The company reported -$3.52 earnings per share for the quarter, missing the consensus estimate of -$0.61 by -$2.91.
Is Metsera, Inc. overvalued?
According to Wall Street analysts Metsera, Inc.’s price is currently Undervalued.
Does Metsera, Inc. pay dividends?
Metsera, Inc. does not currently pay dividends.
What is Metsera, Inc.’s EPS estimate?
Metsera, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Metsera, Inc. have?
Metsera, Inc. has 105,055,534 shares outstanding.
What happened to Metsera, Inc.’s price movement after its last earnings report?
Metsera, Inc. reported an EPS of -$3.52 in its last earnings report, missing expectations of -$0.61. Following the earnings report the stock price went up 10.515%.
Which hedge fund is a major shareholder of Metsera, Inc.?
Currently, no hedge funds are holding shares in MTSR
Metsera, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.00 (96.90% Upside)
$47.00 (96.90% Upside)
Blogger Sentiment
Bullish
MTSR Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Positive
Last 7 Days ―
Last 30 Days ―
Last 30 Days ―
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
172.88%
Trailing 12-Months
Company Description
Metsera, Inc.
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.
MTSR Stock 12 Month Forecast
Average Price Target
$47.00
▲(96.90%Upside)